Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare the time to progression (TTP) of three daily doses of
thalidomide (100, 200 and 400 mg) with high-dose dexamethasone in relapsed refractory
multiple myeloma (MM) patients and to subsequently select the optimum thalidomide dose in
terms of median TPP and toxicity.